JP2019511493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511493A5 JP2019511493A5 JP2018547415A JP2018547415A JP2019511493A5 JP 2019511493 A5 JP2019511493 A5 JP 2019511493A5 JP 2018547415 A JP2018547415 A JP 2018547415A JP 2018547415 A JP2018547415 A JP 2018547415A JP 2019511493 A5 JP2019511493 A5 JP 2019511493A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- copper
- ophthalmic
- corneal
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004087 cornea Anatomy 0.000 claims description 6
- 201000007717 corneal ulcer Diseases 0.000 claims description 3
- 201000002287 Keratoconus Diseases 0.000 claims description 2
- 208000021921 corneal disease Diseases 0.000 claims description 2
- 201000004573 corneal ectasia Diseases 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 7
- 229910052802 copper Inorganic materials 0.000 claims 7
- 239000010949 copper Substances 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000003431 cross linking reagent Substances 0.000 claims 4
- 239000006196 drop Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- -1 depot Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 1
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 claims 1
- 229940116318 copper carbonate Drugs 0.000 claims 1
- 229940108925 copper gluconate Drugs 0.000 claims 1
- 229910000365 copper sulfate Inorganic materials 0.000 claims 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims 1
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 claims 1
- UUYDYUZBCIHUFZ-MDTVQASCSA-L copper;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound [Cu+2].[O-]C(=O)[C@@H](N)CC1=CN=CN1.[O-]C(=O)[C@@H](N)CC1=CN=CN1 UUYDYUZBCIHUFZ-MDTVQASCSA-L 0.000 claims 1
- NZWIFMYRRCMYMN-ACMTZBLWSA-M copper;(2s)-6-amino-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoate Chemical compound [Cu+2].NCCCC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 NZWIFMYRRCMYMN-ACMTZBLWSA-M 0.000 claims 1
- RSJOBNMOMQFPKQ-UHFFFAOYSA-L copper;2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)C(O)C(O)C([O-])=O RSJOBNMOMQFPKQ-UHFFFAOYSA-L 0.000 claims 1
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims 1
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 claims 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 claims 1
- IKUPISAYGBGQDT-UHFFFAOYSA-N copper;dioxido(dioxo)molybdenum Chemical compound [Cu+2].[O-][Mo]([O-])(=O)=O IKUPISAYGBGQDT-UHFFFAOYSA-N 0.000 claims 1
- BQVVSSAWECGTRN-UHFFFAOYSA-L copper;dithiocyanate Chemical compound [Cu+2].[S-]C#N.[S-]C#N BQVVSSAWECGTRN-UHFFFAOYSA-L 0.000 claims 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 1
- PEVJCYPAFCUXEZ-UHFFFAOYSA-J dicopper;phosphonato phosphate Chemical compound [Cu+2].[Cu+2].[O-]P([O-])(=O)OP([O-])([O-])=O PEVJCYPAFCUXEZ-UHFFFAOYSA-J 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 claims 1
- 239000006195 ophthalmic dosage form Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 229930187593 rose bengal Natural products 0.000 claims 1
- 229940081623 rose bengal Drugs 0.000 claims 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims 1
- IRPLSAGFWHCJIQ-UHFFFAOYSA-N selanylidenecopper Chemical compound [Se]=[Cu] IRPLSAGFWHCJIQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010054760 Corneal thinning Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021130408A JP2021185154A (ja) | 2016-03-08 | 2021-08-09 | 交差架橋剤、及び関連する方法 |
| JP2023125896A JP2023153926A (ja) | 2016-03-08 | 2023-08-02 | 交差架橋剤、及び関連する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305227P | 2016-03-08 | 2016-03-08 | |
| US62/305,227 | 2016-03-08 | ||
| PCT/US2016/065215 WO2017155580A1 (en) | 2016-03-08 | 2016-12-06 | Cross-linking agents and associated methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130408A Division JP2021185154A (ja) | 2016-03-08 | 2021-08-09 | 交差架橋剤、及び関連する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511493A JP2019511493A (ja) | 2019-04-25 |
| JP2019511493A5 true JP2019511493A5 (enExample) | 2020-01-23 |
| JP6929010B2 JP6929010B2 (ja) | 2021-09-01 |
Family
ID=59790799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547415A Active JP6929010B2 (ja) | 2016-03-08 | 2016-12-06 | 交差架橋剤、及び関連する方法 |
| JP2021130408A Pending JP2021185154A (ja) | 2016-03-08 | 2021-08-09 | 交差架橋剤、及び関連する方法 |
| JP2023125896A Pending JP2023153926A (ja) | 2016-03-08 | 2023-08-02 | 交差架橋剤、及び関連する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130408A Pending JP2021185154A (ja) | 2016-03-08 | 2021-08-09 | 交差架橋剤、及び関連する方法 |
| JP2023125896A Pending JP2023153926A (ja) | 2016-03-08 | 2023-08-02 | 交差架橋剤、及び関連する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11065275B2 (enExample) |
| EP (2) | EP4324454A3 (enExample) |
| JP (3) | JP6929010B2 (enExample) |
| KR (2) | KR20250026890A (enExample) |
| AU (2) | AU2016396661B2 (enExample) |
| CA (1) | CA3016688A1 (enExample) |
| ES (1) | ES2959242T3 (enExample) |
| WO (1) | WO2017155580A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| EP2830637B1 (en) | 2012-03-29 | 2024-08-21 | Epion Therapeutics, Inc. | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| CA3016688A1 (en) * | 2016-03-08 | 2017-09-14 | University Of Utah Research Foundation | Ophthalmic cross-linking agents and associated methods |
| KR20250109788A (ko) * | 2018-01-05 | 2025-07-17 | 유니버시티 오브 유타 리서치 파운데이션 | 근시 진행의 치료 |
| CN113811527B (zh) | 2019-01-25 | 2024-12-31 | 艾弗德罗股份有限公司 | 双(双吖丙啶)衍生物作为光交联剂治疗角膜扩张性疾病 |
| US20220288114A1 (en) * | 2019-07-11 | 2022-09-15 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| TW202245810A (zh) * | 2021-02-01 | 2022-12-01 | 美商艾維娜傳送系統公司 | 散光之治療 |
| TW202302121A (zh) * | 2021-02-11 | 2023-01-16 | 猶他大學研究基金會 | 近視之治療 |
| CN114082960B (zh) * | 2021-11-11 | 2023-01-17 | 江苏徐工工程机械研究院有限公司 | 轴套的制备方法、轴套及挖掘机 |
| CN115282349A (zh) * | 2022-07-05 | 2022-11-04 | 复旦大学附属眼耳鼻喉科医院 | 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4490389A (en) * | 1976-03-11 | 1984-12-25 | Nelson Research & Development Co. | Contact lens preserving solution containing ascorbic acid or salts thereof |
| JPH05503527A (ja) * | 1990-02-22 | 1993-06-10 | マクノート・ピーティーワイ・リミテッド | 人工涙液 |
| US5270051A (en) * | 1991-10-15 | 1993-12-14 | Harris Donald H | Enzyme-orthokeratology |
| US5997911A (en) * | 1996-08-27 | 1999-12-07 | Brinton Veterinary Supply, Inc. | Composition and method for reducing diarrhea in poultry and swine |
| JPH10273322A (ja) * | 1997-01-30 | 1998-10-13 | Kubota Corp | 抗菌性複合チタン酸化合物およびその製造方法 |
| BR9908692A (pt) * | 1998-03-09 | 2001-12-04 | Ista Pharmaceuticals Inc | Uso de agentes de enrijecimento corneal emortocerotologia enzimática |
| US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
| RU2165749C1 (ru) * | 2000-07-06 | 2001-04-27 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Способ восстановления эндотелия роговицы |
| JP2004513905A (ja) * | 2000-11-16 | 2004-05-13 | ザイラー， ケネス ティー． | 抗真菌爪用組成物および使用方法 |
| CA2574086A1 (en) * | 2004-07-21 | 2006-02-23 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
| US20060134226A1 (en) * | 2004-11-16 | 2006-06-22 | Todd Leonard | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| US20060165611A1 (en) * | 2005-01-26 | 2006-07-27 | National Research Laboratories, Ltd. | Composition for Treating and Preventing Periodontal Disease and Method of Use |
| US20060276777A1 (en) | 2005-04-08 | 2006-12-07 | Coroneo Minas T | Corneal shaping |
| CN101553406B (zh) | 2006-12-07 | 2011-05-04 | 太阳医药高级研发有限公司 | 用于施加微升量的液滴形式的液体的可计量的滴瓶 |
| WO2008124009A2 (en) | 2007-04-02 | 2008-10-16 | The Cleveland Clinic Foundation | Treating glaucoma |
| WO2011041309A1 (en) * | 2009-09-29 | 2011-04-07 | Arresto Biosciences, Inc | Methods and compositions for treatment of ocular fibrosis |
| CN102100693A (zh) * | 2009-12-16 | 2011-06-22 | 沈阳兴齐制药有限公司 | 一种含有肌肽的人工泪液及其制备方法 |
| BRPI1002523B1 (pt) * | 2010-07-14 | 2020-06-02 | Universidade Federal De Minas Gerais | Processo de síntese de complexos de cobre com atividade antitumoral |
| WO2014065863A1 (en) | 2012-10-22 | 2014-05-01 | The Regents Of The University Of California | Compositions and methods for promoting collagen-crosslinking |
| RU2683651C2 (ru) * | 2013-06-18 | 2019-04-01 | Иван Дмитриевич Захаров | Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе |
| DE102014012675A1 (de) | 2014-08-26 | 2016-03-03 | Wavelight Gmbh | Vernetzung von Augengewebe |
| LT3280412T (lt) * | 2015-04-09 | 2019-11-25 | Laboratori Baldacci Spa | Pirolidono karboksirūgštis (pkr), skirta naudoti oftalmologijoje |
| CA3016688A1 (en) * | 2016-03-08 | 2017-09-14 | University Of Utah Research Foundation | Ophthalmic cross-linking agents and associated methods |
| KR20250109788A (ko) * | 2018-01-05 | 2025-07-17 | 유니버시티 오브 유타 리서치 파운데이션 | 근시 진행의 치료 |
-
2016
- 2016-12-06 CA CA3016688A patent/CA3016688A1/en active Pending
- 2016-12-06 KR KR1020257005160A patent/KR20250026890A/ko active Pending
- 2016-12-06 WO PCT/US2016/065215 patent/WO2017155580A1/en not_active Ceased
- 2016-12-06 EP EP23192363.2A patent/EP4324454A3/en active Pending
- 2016-12-06 JP JP2018547415A patent/JP6929010B2/ja active Active
- 2016-12-06 AU AU2016396661A patent/AU2016396661B2/en active Active
- 2016-12-06 ES ES16893791T patent/ES2959242T3/es active Active
- 2016-12-06 EP EP16893791.0A patent/EP3426262B1/en active Active
- 2016-12-06 US US16/083,865 patent/US11065275B2/en active Active
- 2016-12-06 KR KR1020187028639A patent/KR102771170B1/ko active Active
-
2021
- 2021-06-28 US US17/360,610 patent/US20210322470A1/en active Pending
- 2021-08-09 JP JP2021130408A patent/JP2021185154A/ja active Pending
-
2023
- 2023-04-12 AU AU2023202236A patent/AU2023202236B2/en active Active
- 2023-08-02 JP JP2023125896A patent/JP2023153926A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511493A5 (enExample) | ||
| JP7329019B2 (ja) | 老視を治療するための組成物及び方法 | |
| JP7026189B2 (ja) | 眼の屈折異常の治療のための貯蔵安定な組成物および方法 | |
| JP2019508472A (ja) | 老視の処置のための組成物及び方法 | |
| US10335367B2 (en) | Use of selected anticholinergic zwitterions | |
| CN108601768A (zh) | 用于治疗老花眼的组合物 | |
| TW202333700A (zh) | 用於治療眼病之組成物及方法 | |
| JP6449774B2 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 | |
| JP2022541152A (ja) | 多形態眼球製剤および治療法 | |
| JPWO2019136358A5 (enExample) | ||
| JP2024508706A (ja) | 近視の治療 | |
| CA3041626C (en) | Ophthalmic composition for lowering intraocular pressure | |
| RU2669570C2 (ru) | Офтальмологическая композиция для цвиттерионных мягких контактных линз | |
| JPWO2021007578A5 (enExample) | ||
| CN119235862A (zh) | 选择性syk抑制剂的使用方法及药物组合物 | |
| HK40014460A (en) | Aceclidine for use in the treatment of presbyopia |